Real-world pathologic complete response after neoadjuvant chemotherapy in a safety-net breast cancer population.
556 Background: While clinical trials report subtype-specific pathologic complete response (pCR) rates, real-world data from safety-net health systems remain limited and underrepresented in major neoadjuvant trials. Our urban safety-net patient population in Oakland, CA, provides a unique view of real-world neo...